NCT06647095View on ClinicalTrials.gov

New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

CompletedOBSERVATIONAL
Enrollment

172

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2024

Conditions
HealthySimple Steatosis (SS)Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
DIETARY_SUPPLEMENT

D-Limonene Gelcaps

Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups

DIETARY_SUPPLEMENT

Fish Oil Concentrate, 1000 Mg Oral Capsule

Capsules containing fish oil will be optionally given during the breath test to all participants of all groups

Trial Locations (2)

12800

General University Hospital in Prague, Prague

46001

Regional Hospital Liberec, Liberec

All Listed Sponsors
lead

General University Hospital, Prague

OTHER

NCT06647095 - New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Biotech Hunter | Biotech Hunter